About the bill
A bill to eliminate requirements to undertake duplicative clinical testing of new pharmaceutical drugs, vaccines, biological products, or medical devices, when such duplication is inconsistent with relevant ethical norms.
The bill’s titles are written by its sponsor.
Earlier Version — Introduced
This activity took place on a related bill, S. 3921 (111th).
This is the first step in the legislative process.
Links & tools
Click a format for a citation suggestion:
Civic Impulse. (2016). S. 3506 — 112th Congress: Ethical Pathway Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s3506
“S. 3506 — 112th Congress: Ethical Pathway Act of 2012.” www.GovTrack.us. 2012. July 30, 2016 <https://www.govtrack.us/congress/bills/112/s3506>
|title=S. 3506 (112th)
|accessdate=July 30, 2016
|author=112th Congress (2012)
|date=August 2, 2012
|quote=Ethical Pathway Act of 2012